Trimeric motifs and their application in the expression of RSV trimer protein

By designing α-helix structured trimer motif peptides HTe1-HTer20 or MXP1-MXP11, the problems of incomplete trimerization and structural instability of recombinant F protein were solved, achieving high secretory expression and stable conformation of RSV F protein, and enhancing the neutralizing antibody titer of the vaccine.

CN123106847APending Publication Date: 2026-11-17INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611186595.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-06-14
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

In in vitro expression systems, incomplete trimerization or structural instability of recombinant F protein leads to conformational epitope masking, significantly reducing the neutralizing antibody titer of the vaccine. Existing trimer motif peptides may mask the functional epitopes of the F protein.

Method used

We designed and used trimeric motif peptides HTe1-HTer20 or MXP1-MXP11 with α-helical secondary structures, and stabilized the trimeric structure by adding them to the ends of heterologous proteins, thereby achieving high secretory expression and full exposure of neutralizing epitopes.

Benefits of technology

This study achieved high secretory expression and stable trimer conformation of RSV F protein, enhanced neutralizing antibody titer, resisted the destruction of detergents such as SDS, and improved the immune efficacy of the vaccine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106847A_ABST
    Figure CN123106847A_ABST
Patent Text Reader

Abstract

This invention discloses a trimer motif and its application in the expression of RSV trimer protein, which solves the problems of epitope masking and low expression levels in trimer protein vaccines, and achieves efficient and high-expression RSV trimer protein vaccine expression.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of Chinese Patent Application No. 202510794802.2, entitled "Trimeric motif and its application in expressing RSV trimer protein", filed on June 14, 2025. Technical Field

[0002] This invention relates to the field of genetic engineering vaccine technology, and in particular to a trimer motif with an α-helix structure and its application in achieving high secretory expression of trimer protein vaccines. Background Technology

[0003] The respiratory syncytial virus (RSV) fusion protein (F protein) is a key antigen mediating viral fusion with the host cell membrane. It has different conformations, such as pre-F and post-F. The former is a metastable trimer structure that exposes multiple neutralizing antibody epitopes; the latter, although highly stable, loses neutralizing epitopes. However, in in vitro expression systems, recombinant F protein often suffers from conformational epitope masking due to incomplete trimerization or structural instability, significantly reducing the neutralizing antibody titer of the vaccine.

[0004] Currently, trimerization is primarily driven by the HRB domain (Heptad Repeat B) of the native F protein or by exogenous motif peptides (such as T4 phage Foldon). While traditional motif peptides (such as GCN4 or Isoleucine Zipper) can improve trimer yield, their overly rigid structures may mask functional epitopes of the F protein. Therefore, there is an urgent need to develop novel trimer motif peptides that can maintain high expression levels while preserving the trimer conformation to fully expose neutralizing epitopes. Summary of the Invention

[0005] The purpose of this invention is to provide a trimerized motif peptide for high secretory expression in trimeric protein vaccines and its application in the construction of protein vaccines.

[0006] Provides a trimerized motif peptide, characterized in that it is specifically HTe1-HTer20 or MXP1-MXP11; preferably, it is selected from HTe2, HTe7, HTe18, HTe20 or MXP6.

[0007] A trimerized motif peptide is provided, characterized in that it has an amino acid sequence as shown in any of SEQ ID NO:2-21 or SEQ ID NO:43-53; in some embodiments, it has an amino acid sequence as shown in any of SEQ ID NO:2-20 or SEQ ID NO:43-53; in some embodiments, the trimerized motif peptide has an amino acid sequence as shown in any of SEQ ID NO:3, 8, 19 or SEQ ID NO:48;

[0008] In some embodiments, the trimerizing motif peptide is encoded by a nucleotide sequence as shown in SEQ ID NO:22-41 or SEQ ID NO:54-64; preferably, the trimerizing motif peptide is encoded by a nucleotide sequence as shown in SEQ ID NO:23, 28, 39, 41 or SEQ ID NO:59.

[0009] Preferably, the trimerizing motif peptide is used to construct a trimer protein. Preferably, the trimerizing motif peptide is used to construct a recombinant RSV F protein.

[0010] A recombinant RSV F protein is provided, characterized in that it comprises any of the trimerized motif peptides described above.

[0011] Preferably, the recombinant RSV F protein is a homotrimer or heterotrimer.

[0012] Preferably, the recombinant RSV F protein comprises an F1 polypeptide and / or an F2 polypeptide. More preferably, it comprises both an F1 polypeptide and an F2 polypeptide. More preferably, the F1 polypeptide and the F2 polypeptide are directly linked or indirectly linked via a linker. Even more preferably, the F1 polypeptide is as shown in SEQ ID NO:68, and the F2 polypeptide is as shown in SEQ ID NO:67.

[0013] A polynucleotide is provided, characterized in that the polynucleotide encodes any of the trimerized motif peptides described above or any of the recombinant RSV F proteins described above. Preferably, the polynucleotide is as shown in SEQ ID NO:22-41 or SEQ ID NO:54-64; more preferably, the polynucleotide is as shown in SEQ ID NO:23, 28, 39, 41 or SEQ ID NO:59.

[0014] A carrier is provided, characterized in that the carrier carries any of the polynucleotides described above.

[0015] The cell is provided, characterized in that the cell carries any of the polynucleotides, vectors, and / or expresses any of the trimerized motif peptides or recombinant RSV F proteins described above.

[0016] Preferably, the cells are a eukaryotic expression system. More preferably, the eukaryotic expression system is a mammalian cell. Even more preferably, the mammalian cells include CHO, 293F, etc. Most preferably, the mammalian cells are 293F cells.

[0017] An immunogenic composition is provided, characterized in that it comprises any of the recombinant RSV F proteins described above, and a pharmaceutically acceptable carrier or excipient; optionally, it further comprises an adjuvant, said adjuvant including, but not limited to, one or more of aluminum adjuvant, CpG adjuvant, MF59 adjuvant, AS01 adjuvant, AS02 adjuvant, AS03 adjuvant and lipid nanoparticle adjuvant.

[0018] The above-described trimerized motif peptides, recombinant RSV F proteins, polynucleotides, vectors, cells, and / or immunogenic compositions are used in the following (1)-(4):

[0019] (1) Preparation of antibodies that bind to respiratory syncytial virus antigenic epitopes;

[0020] (2) To prepare vaccines for the prevention and / or treatment of respiratory syncytial virus infection;

[0021] (3) Preparation of respiratory syncytial virus diagnostic products;

[0022] (4) Detection of respiratory syncytial virus.

[0023] In some implementations, the application is for the detection of respiratory syncytial virus for non-diagnostic and non-therapeutic purposes.

[0024] Compared with the prior art, the present invention has the following beneficial effects:

[0025] Firstly, the present invention designs a trimer motif peptide with an α-helix secondary structure, which can be added as an exogenous sequence to the end of a heterologous protein, thereby stabilizing the structure of the heterologous protein in a trimer state.

[0026] Secondly, the present invention has a trimer motif peptide with an α-helix secondary structure, which can achieve high secretory expression of RSV F protein.

[0027] Thirdly, compared with the trimer motif peptides of natural proteins, the trimer motif peptides modified in this invention are more stable and can resist the damage of detergents such as SDS. Attached Figure Description

[0028] Figure 1 These are the predicted secondary structure results of the HTr1-HTer20 amino acid sequences.

[0029] Figure 2These are the predicted secondary structure results of the amino acid sequences of MXP1-MXP11.

[0030] Figure 3 These are the results of RSV F protein expression detection for different trimer motif peptides (non-denaturing, non-reducing SDS-PAGE).

[0031] Figure 4 These are the results of RSV F protein expression detection for different trimer motif peptide segments (non-denaturing, non-reducing protein gel WB). Detailed Implementation

[0032] The present invention will now be described in detail with reference to embodiments, but the embodiments provided herein are for illustrative purposes only and are not intended to limit the present invention.

[0033] the term

[0034] The term "RSV F protein" or "F protein," meaning fusion protein, is an RSV envelope glycoprotein that facilitates the fusion of the RSV viral membrane and the host cell membrane. The RSV F protein is initially synthesized as a single polypeptide precursor of approximately 574 amino acids, named F0. The extracellular portion of the RSV F protein includes the F2 protein and the F1 extracellular domain.

[0035] The terms “F0 peptide”, “F1 peptide”, and “F2 peptide” include peptides derived from wild-type sequences of different subtypes of RSV, or modified peptides, including but not limited to amino acid substitutions, insertions and / or deletions.

[0036] The terms "F protein", "F polypeptide", and "RSV F protein" refer to one or all of the following in any state: "F0 polypeptide", "F1 polypeptide", and "F2 polypeptide"; they also include complete or truncated fragments, including proteins / polypeptides whose sequences have been partially mutated or modified but still retain complete or partial original functions.

[0037] The terms “HTer”, “trimeric motif peptide”, “trimerization motif peptide”, “trimerization domain”, and “trimerization sequence” are used interchangeably throughout the text and refer to the amino acid sequence in a polypeptide / protein sequence that promotes the assembly of polypeptide / protein into a trimer.

[0038] The terms “linker,” “connector,” “spacer,” or “spacer sequence” refer to the linking of two molecules into a single continuous molecule. Non-limiting examples of linkers include glycine-serine peptide linkers and segments of any length between amino acids 514 and 524 of the RSV F protein.

[0039] "Pharmaceutically acceptable carrier" or "excipient" refers to pharmaceutically acceptable excipients, which are known excipients and additives used in the production of pharmaceuticals and the dispensing of prescriptions; they are known to the public and can be selected by those skilled in the art.

[0040] The various terms and phrases used in this invention have their general meanings known to those skilled in the art. Nevertheless, this invention still intends to provide a more detailed description and explanation of these terms and phrases. In the event of any inconsistency between the terms and phrases mentioned and their known meanings, the meanings expressed in this invention shall prevail.

[0041] Example 1: Design of Hter amino acid sequences with α-helix secondary structure

[0042] HTe sequences were designed based on MTI (GGSGGIKEEIAKIKEEIAKIKEKIAEIEKRIAEIEKRIAGGCC; SEQ ID NO:1). Secondary structure prediction of the modified sequences was performed using protein secondary structure prediction software. Preliminary expression validation identified 20 HTe-related sequences that can be used for the high-secretionary expression of the trimeric protein. The amino acid sequences (SEQ ID NO:2-21) and nucleotide sequences (SEQ ID NO:22-41) of HTe1-HTer20 are shown in Table 1. Secondary structure prediction of the amino acid sequences is shown in […]. Figure 1 .

[0043] Table 1: Amino acid and nucleotide sequences of HTe1-HTer20

[0044]

[0045]

[0046]

[0047] Example 2: Design of MXP amino acid sequences with α-helix secondary structure

[0048] MXP sequences were designed based on the trimer motif peptide of maternal protein 1 chondroma matrix protein (CACESLVKFQAKVEGLLQALTRKLEAVSKRLAILENTVV; SEQ ID NO:42). The secondary structure of the modified sequences was predicted using protein secondary structure prediction software. Preliminary expression validation identified 11 MXP-related sequences that can be used for subsequent high-secretionary expression of the trimer protein. The amino acid sequences (SEQ ID NO:43-53) and nucleotide sequences (SEQ ID NO:54-64) of MXP1-MXP11 are shown in Table 2. Secondary structure prediction of the amino acid sequences is shown in [Table 2]. Figure 2 .

[0049] Table 2: Amino acid and nucleotide sequences of MXP1-MXP11

[0050]

[0051] Example 3: Plasmid construction and secretory protein expression of pre-fusion RSV F peptide using trimerized motif peptides

[0052] The amino acid sequence of the RSV F protein was modified, and the modified sequence was named C1-5, which contains amino acids 26-105 of the F2 polypeptide + linker 1 (GGSGGSGGS; SEQ ID NO:65) + amino acids 147-513 of the F1 polypeptide. A partial sequence is shown below:

[0053]

[0054] Note: The italicized part of the sequence is the signal peptide; the bold part of the sequence is F2 polypeptide amino acid 26-105; the single underlined part of the sequence is linker 2: (G2S)3; the double underlined part of the sequence is F1 polypeptide amino acid 147-513.

[0055] F2 polypeptide amino acids 26-105

[0056]

[0057] > F1 polypeptide amino acid 147-513

[0058]

[0059] > Connector 2

[0060]

[0061] The designed trimerized motif peptide with an α-helix secondary structure, including the HTe and MXP amino acid sequences, was linked to the C-terminus of the RSV F protein C1-5 sequence via linker 3 (GGSGG; SEQ IN NO:70). The correct ligation was confirmed by first-generation sequencing. The expression vector containing the fusion gene was transfected into 293F suspension cells using PEI reagent. After culturing for 5-7 days, the supernatant was harvested for verification of RSV F protein trimer hypersecretion.

[0062] The experimental results are shown in Figure 3 (Non-denaturing, non-reducing SDS-PAGE) and Figure 4(Non-denaturing, non-reducing protein gel WB). The results showed that the candidate sequences with high protein expression levels were HTe2, HTe4, HTe5, HTe7, HTe8, HTe9, HTe10, HTe12, HTe13, HTe17, HTe18, HTe20, MXP6, MXP7, MXP8, MXP9, and MXP10. Among them, HTe2, HTe7, HTe18, and HTe20 had the highest protein expression levels and can be used as the most preferred trimeric motif peptides for the secretory expression of trimeric proteins.

[0063] Example 4: Identification of pre- and post-fusion epitopes in RSV F trimer protein constructed using HTe amino acid sequences with α-helical structures.

[0064] Different monoclonal antibodies can recognize different epitopes of the RSV F protein. Among them, monoclonal antibodies that recognize only the PreF epitope Ø include D25, 8897, 5C4, and AM22; monoclonal antibodies that recognize both PreF and PostF epitopes II include Palivizumab and Motavizumab; monoclonal antibodies that recognize both PreF and PostF epitopes IV include 101F; and monoclonal antibodies that recognize the F protein trimer include AM14. Based on monoclonal antibodies that recognize different epitopes, our laboratory previously established a double-antibody sandwich ELISA method for total F protein and conformational PreF protein, which can be used to detect the expression levels and PreF protein proportions of different trimer motif peptides in F protein.

[0065] The ELISA results are shown in Table 3 (protein expression levels are in μg / mL). MOTA-D25-HRP (coating antibody Motavizumab, detection antibody D25) and MOTA-AM22-HRP (coating antibody Motavizumab, detection antibody AM22) were used to detect the pre-fusion protein content and epitope identification of RSV F protein; MOTA-101F-HRP (coating antibody Motavizumab, detection antibody 101F) was used to detect the post-fusion protein content and epitope identification.

[0066] The results showed that the RSV F trimer protein constructed from HTe2, HTe3, HTe4, HTe5, HTe6, HTe7, HTe8, HTe13, HTe15, HTe18, and HTe20 had the highest expression levels and the highest proportion of pre-fusion conformation. The optimal composition was HTe2, HTe5, HTe6, HTe7, HTe8, HTe13, HTe18, and HTe20, which can be used as the most preferred trimer motif peptides for the secretory expression of trimer proteins.

[0067] In summary, the expression levels of binding proteins ( Figure 3 and Figure 4 Based on the results of conformational characterization (Table 3), the optimal trimer motif peptides were HTe2, HTe7, HTe18, and HTe20. Compared with the control MTI motif peptides, these motif peptides showed higher expression levels, a higher proportion of pre-fusion conformation, and more stable trimer structures.

[0068] Table 3: Identification of RSV F protein constructed based on HTr1-HTer20 sequences

[0069]

[0070] Example 5: Identification of pre- and post-fusion epitopes of RSV F trimer protein constructed using MXP amino acid sequences with α-helical structures.

[0071] The detection and identification methods of Example 4 were used to detect the pre-fusion and post-fusion protein content of RSV F protein and to identify epitopes.

[0072] The experimental results are shown in Table 4 (protein expression levels are in μg / mL). The results indicate that the RSV F trimer proteins constructed from MXP6, MXP7, MXP8, MXP9, and MXP10 had the highest expression levels and the highest proportion of pre-fusion conformation. However, due to the presence of MXP9... Figure 3 and Figure 4 No trimeric conformation was observed in the sample; therefore, MXP6 was the optimal choice as the preferred trimeric motif peptide for the secretory expression of the trimeric protein. Compared to the control MXP motif peptide, the MXP6 motif peptide exhibited higher expression levels, a higher proportion of the pre-fusion conformation, and a more stable trimeric structure.

[0073] Table 4: Identification of RSV F proteins constructed based on MXP1-MXP11 sequences

[0074] This specific embodiment is merely an explanation of the present invention and is not intended to limit the invention. After reading this specification, those skilled in the art can make modifications to this embodiment without contributing any inventive step, but such modifications are protected by patent law as long as they are within the scope of the claims of the present invention.

Claims

1. A trimerized motif peptide, characterized in that, It has an amino acid sequence as shown in any of SEQ ID NO:2-20 or 43-53; Preferably, the trimerized motif peptide has an amino acid sequence as shown in any one of SEQ ID NO:3, 8, 19, 48.

2. The trimerized motif peptide according to claim 1, characterized in that, The trimerized motif peptide was used to construct the recombinant RSV F protein.

3. Recombinant RSV F protein, characterized in that, It includes the trimerized motif peptide as described in any one of claims 1-2, wherein the recombinant RSV F protein is a homotrimer or heterotrimer.

4. The recombinant RSV F protein according to claim 3, characterized in that, It contains F1 polypeptide and / or F2 polypeptide, wherein the F1 polypeptide and F2 polypeptide are directly linked or indirectly linked through a linker.

5. The recombinant RSV F protein according to any one of claims 3-4, characterized in that, The F1 polypeptide is shown in SEQ ID NO:68, and the F2 polypeptide is shown in SEQ ID NO:

67.

6. A polynucleotide, characterized in that, The polynucleotide encodes the trimerized motif peptide of any one of claims 1-2 or the recombinant RSV F protein of any one of claims 3-5.

7. A carrier, characterized in that, The vector carries the polynucleotide of claim 6.

8. A cell, characterized in that, The cell carries the polynucleotide of claim 6, contains the vector of claim 7, and / or expresses the trimerized motif peptide of any one of claims 1-2 or the recombinant RSV F protein of any one of claims 3-5; preferably, the cell is a eukaryotic expression system.

9. An immunogenic composition, characterized in that, It comprises the recombinant RSV F protein as described in any one of claims 3-5, and a pharmaceutically acceptable carrier or excipient; optionally, it further comprises an adjuvant, said adjuvant comprising one or more of aluminum adjuvant, CpG adjuvant, MF59 adjuvant, AS01 adjuvant, AS02 adjuvant, AS03 adjuvant, and lipid nanoparticle adjuvant.

10. The trimerized motif peptide of any one of claims 1-2, the recombinant RSV F protein of any one of claims 3-5, the polynucleotide of claim 6, the vector of claim 7, the cell of claim 8, and / or the immunogenic composition of claim 9, used in any one of the following (1)-(4): (1) Preparation of antibodies that bind to respiratory syncytial virus antigenic epitopes; (2) To prepare vaccines for the prevention and / or treatment of respiratory syncytial virus infection; (3) Preparation of respiratory syncytial virus diagnostic products; (4) Detection of respiratory syncytial virus.